Development and evaluation of co-formulated docetaxel and curcumin biodegradable nanoparticles for parenteral administration.

Context: Technology for development of biodegradable nanoparticles encapsulating combinations for enhanced efficacy.

Objective: To develop docetaxel (DTX) and curcumin (CRM) co-encapsulated biodegradable nanoparticles for parenteral administration with potential for prolonged release and decreased toxicity.

Materials And Methods: Modified emulsion solvent-evaporation technique was employed in the preparation of the nanoparticles optimized by the face centered-central composite design (FC-CCD).